Payment overview · 2025
General Payments
$1,784.49
107 reported records · 26 companies
Healthcare provider profile · identity verified
Michael D Dupre, MD
Allopathic & Osteopathic Physicians|Family Medicine · PELL CITY, AL · NPI 1104802495
Verified facts
What the public records show
CMS Open Payments records show Michael D Dupre, MD received $1,784.49 in general payments during 2025 across 107 reported records.
ABBVIE INC. accounted for 17.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Eliquis, Farxiga, Kerendia, Linzess, Nurtec Odt, Otezla, Ozempic, Shingrix, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 390 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $302.84 | 17.0% | 29 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $275.14 | 15.4% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $160.45 | 9.0% | 12 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $125.27 | 7.0% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $98.02 | 5.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $95.79 | 5.4% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $69.00 | 3.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $59.07 | 3.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.72 | 3.3% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $55.87 | 3.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $54.69 | 3.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $52.60 | 3.0% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $50.92 | 2.9% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $47.62 | 2.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.90 | 2.1% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $34.35 | 1.9% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $32.80 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.14 | 1.8% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.46 | 1.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.97 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.66 | 1.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.65 | 1.1% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $17.24 | 1.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.15 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.52 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.65 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,784.49 | 107 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $159.34 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $150.62 | 16 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $125.27 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $120.16 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $120.16 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $114.94 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $100.29 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $95.79 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $79.90 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $79.90 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $72.32 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $72.32 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.30 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $54.69 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.67 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $52.60 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $50.92 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $47.62 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.03 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $44.29 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.35 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $37.90 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.44 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $34.35 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $32.80 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.14 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $19.50 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 11 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 206 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 180 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 390 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 189 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
180 | 54 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
189 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
390 | 84 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
206 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1140 | 291 |
| Alprazolam | Alprazolam | 1110 | 207 |
| Atorvastatin Calcium | Atorvastatin Calcium | 899 | 255 |
| Pantoprazole Sodium | Pantoprazole Sodium | 861 | 233 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 720 | 228 |
| Levothyroxine Sodium | Levothyroxine Sodium | 659 | 170 |
| Lisinopril | Lisinopril | 601 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 549 | 167 |
| Metformin Hcl Er | Metformin Hcl | 534 | 151 |
| Gabapentin | Gabapentin | 490 | 123 |
| Tramadol Hcl | Tramadol Hcl | 446 | 100 |
| Omeprazole | Omeprazole | 440 | 122 |
| Ozempic | Semaglutide | 390 | 84 |
| Pioglitazone Hcl | Pioglitazone Hcl | 370 | 110 |
| Fluoxetine Hcl | Fluoxetine Hcl | 369 | 108 |
| Meloxicam | Meloxicam | 354 | 109 |
| Potassium Chloride | Potassium Chloride | 350 | 86 |
| Trazodone Hcl | Trazodone Hcl | 350 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 337 | 95 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 331 | 120 |
| Montelukast Sodium | Montelukast Sodium | 322 | 86 |
| Citalopram Hbr | Citalopram Hydrobromide | 312 | 87 |
| Carvedilol | Carvedilol | 310 | 90 |
| Simvastatin | Simvastatin | 297 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 286 | 73 |
| Pregabalin | Pregabalin | 286 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 285 | 72 |
| Furosemide | Furosemide | 273 | 81 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 269 | 65 |
| Prednisone | Prednisone | 267 | 169 |
| Bupropion Xl | Bupropion Hcl | 257 | 69 |
| Clonazepam | Clonazepam | 246 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 76 |
| Methocarbamol | Methocarbamol | 225 | 79 |
| Quetiapine Fumarate | Quetiapine Fumarate | 220 | 51 |
| Metformin Hcl | Metformin Hcl | 214 | 61 |
| Aripiprazole | Aripiprazole | 210 | 59 |
| Losartan Potassium | Losartan Potassium | 209 | 72 |
| Eliquis | Apixaban | 206 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 189 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 188 | 56 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 184 | 41 |
| Galantamine Hbr | Galantamine Hbr | 183 | 40 |
| Levofloxacin | Levofloxacin | 182 | 158 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 182 | 38 |
| Linzess | Linaclotide | 180 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 43 |
| Allopurinol | Allopurinol | 165 | 40 |
| Mounjaro | Tirzepatide | 161 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 154 | 38 |
| Sertraline Hcl | Sertraline Hcl | 151 | 39 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 150 | 48 |
| Temazepam | Temazepam | 148 | 37 |
| Jardiance | Empagliflozin | 146 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 33 |
| Megestrol Acetate | Megestrol Acetate | 143 | 37 |
| Buspirone Hcl | Buspirone Hcl | 137 | 30 |
| Etodolac | Etodolac | 125 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 33 |
| Meclizine Hcl | Meclizine Hcl | 123 | 43 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 121 | 106 |
| Ramipril | Ramipril | 118 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 32 |
| Baclofen | Baclofen | 111 | 38 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 111 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 111 | 22 |
| Sucralfate | Sucralfate | 108 | 28 |
| Celecoxib | Celecoxib | 105 | 30 |
| Memantine Hcl | Memantine Hcl | 103 | 27 |
| Estradiol | Estradiol | 102 | 26 |
| Ondansetron Odt | Ondansetron | 100 | 47 |
| Famotidine | Famotidine | 99 | 34 |
| Lorazepam | Lorazepam | 99 | 19 |
| Fluconazole | Fluconazole | 98 | 76 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 96 | 62 |
| Atenolol | Atenolol | 95 | 29 |
| Ipratropium Bromide | Ipratropium Bromide | 95 | 32 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 92 | 19 |
| Alendronate Sodium | Alendronate Sodium | 90 | 34 |
| Glimepiride | Glimepiride | 90 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 90 | 12 |
| Valacyclovir | Valacyclovir Hcl | 88 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 86 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 85 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 83 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 81 | 14 |
| Mupirocin | Mupirocin | 78 | 44 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 22 |
| Fenofibrate | Fenofibrate | 64 | 21 |
| Ibuprofen | Ibuprofen | 64 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 64 | 55 |
| Ezetimibe | Ezetimibe | 63 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 62 | 27 |
| Risedronate Sodium | Risedronate Sodium | 61 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 58 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 58 | 13 |
| Methimazole | Methimazole | 55 | 15 |
| Mirtazapine | Mirtazapine | 55 | 18 |
| Farxiga | Dapagliflozin Propanediol | 53 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 20 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 11 |
| Flecainide Acetate | Flecainide Acetate | 51 | suppressed |
| Telmisartan | Telmisartan | 51 | 15 |
| Benazepril Hcl | Benazepril Hcl | 50 | 18 |
| Etodolac Er | Etodolac | 50 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 15 |
| Synthroid | Levothyroxine Sodium | 49 | 12 |
| Propranolol Hcl | Propranolol Hcl | 48 | suppressed |
| Bumetanide | Bumetanide | 47 | 15 |
| Methylprednisolone | Methylprednisolone | 47 | 46 |
| Donepezil Hcl | Donepezil Hcl | 46 | 11 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Methotrexate | Methotrexate Sodium | 46 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 46 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | suppressed |
| Valsartan | Valsartan | 44 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | 11 |
| Spironolactone | Spironolactone | 43 | 17 |
| Topiramate | Topiramate | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | suppressed |
| Myrbetriq | Mirabegron | 41 | 11 |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Lovastatin | Lovastatin | 40 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Eszopiclone | Eszopiclone | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 36 | 22 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 36 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 11 |
| Primidone | Primidone | 35 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Colchicine | Colchicine | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 32 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 28 | 11 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 20 |
| Digoxin | Digoxin | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 18 |
| Clarithromycin | Clarithromycin | 26 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Metronidazole | Metronidazole | 25 | 16 |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Pentoxifylline | Pentoxifylline | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Testosterone | Testosterone | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 16 |
| Vilazodone Hcl | Vilazodone Hcl | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Nystatin | Nystatin | 22 | 15 |
| Trulicity | Dulaglutide | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 18 |
| Cilostazol | Cilostazol | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 14 |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Otezla | Apremilast | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Armodafinil | Armodafinil | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 17 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Progesterone | Progesterone, Micronized | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Cholestyramine Light | Cholestyramine | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,784.49 · 107 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AREXVY, Auvelity, Azstarys, BREZTRI, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GEMTESA, IBSRELA, INGREZZA, KRYSTEXXA, Kerendia, LAGEVRIO, LINZESS, NURTEC ODT, NUZYRA, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VENASEAL, VIBERZI, VRAYLAR, Wegovy, XHANCE, XIFAXAN, XYOSTED, ZAVZPRET, ZORYVE, t:slim X2 Insulin Pump with Control-IQ | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error